Outcomes in LCH-II MS-LCH risk patients
| . | Therapy arm, all risk patients . | Risk organ involvement . | ||||
|---|---|---|---|---|---|---|
| Arm A . | Arm B . | P . | RO+ . | RO− . | P . | |
| Rapid (week 6) response | ||||||
| Responders/total (%) | 53/84 (63) | 65/91 (71) | .24 | 83/133 (62) | 35/42 (83) | .01 |
| Survival | ||||||
| Deaths/total | 23/88 | 19/95 | — | 42/138 | 0/43 | — |
| 5-y pSU, % plus or minus SE | 74 ± 5 | 79 ± 4 | .26 | 69 ± 4 | 100 | <.001 |
| Disease resolution | ||||||
| Patients NAD/total evaluated | 55/85 | 69/93 | — | 84/135 | 40/43 | — |
| Cumulative incidence, % plus or minus SE | .036 | <.001 | ||||
| 1 y | 49 ± 6 | 62 ± 5 | — | 49 ± 4 | 78 ± 7 | — |
| 3 y | 64 ± 6 | 76 ± 5 | — | 63 ± 4 | 94 ± 4 | — |
| 5 y | 72 ± 5 | 79 ± 4 | — | 68 ± 4 | 100 | — |
| Reactivations | ||||||
| Patients/total NAD | 22/52 | 31/69 | — | 33/81 | 20/40 | — |
| 3-y cumulative incidence, % plus or minus SE | 46 ± 7 | 46 ± 6 | .62 | 44 ± 6 | 52 ±10 | .31 |
| Reactivations in risk organs | 4 | 9 | — | 13 | 0 | — |
| 3-y cumulative incidence, % plus or minus SE | 8 ± 4 | 13 ± 4 | .44 | 17 ± 6 | 0 | .44 |
| Permanent consequences | ||||||
| Patients with PC/total | 28/65 | 26/76 | — | 39/103 | 15/38 | — |
| 5-y cumulative incidence, % plus or minus SE | 43 ± 7 | 37 ± 6 | .25 | 39 ± 5 | 40 ± 9 | .77 |
| . | Therapy arm, all risk patients . | Risk organ involvement . | ||||
|---|---|---|---|---|---|---|
| Arm A . | Arm B . | P . | RO+ . | RO− . | P . | |
| Rapid (week 6) response | ||||||
| Responders/total (%) | 53/84 (63) | 65/91 (71) | .24 | 83/133 (62) | 35/42 (83) | .01 |
| Survival | ||||||
| Deaths/total | 23/88 | 19/95 | — | 42/138 | 0/43 | — |
| 5-y pSU, % plus or minus SE | 74 ± 5 | 79 ± 4 | .26 | 69 ± 4 | 100 | <.001 |
| Disease resolution | ||||||
| Patients NAD/total evaluated | 55/85 | 69/93 | — | 84/135 | 40/43 | — |
| Cumulative incidence, % plus or minus SE | .036 | <.001 | ||||
| 1 y | 49 ± 6 | 62 ± 5 | — | 49 ± 4 | 78 ± 7 | — |
| 3 y | 64 ± 6 | 76 ± 5 | — | 63 ± 4 | 94 ± 4 | — |
| 5 y | 72 ± 5 | 79 ± 4 | — | 68 ± 4 | 100 | — |
| Reactivations | ||||||
| Patients/total NAD | 22/52 | 31/69 | — | 33/81 | 20/40 | — |
| 3-y cumulative incidence, % plus or minus SE | 46 ± 7 | 46 ± 6 | .62 | 44 ± 6 | 52 ±10 | .31 |
| Reactivations in risk organs | 4 | 9 | — | 13 | 0 | — |
| 3-y cumulative incidence, % plus or minus SE | 8 ± 4 | 13 ± 4 | .44 | 17 ± 6 | 0 | .44 |
| Permanent consequences | ||||||
| Patients with PC/total | 28/65 | 26/76 | — | 39/103 | 15/38 | — |
| 5-y cumulative incidence, % plus or minus SE | 43 ± 7 | 37 ± 6 | .25 | 39 ± 5 | 40 ± 9 | .77 |
— indicates not applicable.